0257 GMT - Ansell is likely to be the Australian healthcare stock that is most exposed to the impact of U.S. tariffs, Citi analysts write in a note. They acknowledge that breath-tech maker ResMed and medical-tech provider Nanosonics are probably impacted, given their manufacturing footprints, but not to the same extent as Ansell. The personal-protective equipment maker sources a majority of its products from Malaysia and Sri Lanka, both of which are among the countries hardest hit by tariffs, generating more than 40% of its revenue from the U.S. The exclusion of pharmaceuticals from tariffs is a relief for vaccine maker CSL, they add. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 03, 2025 22:57 ET (02:57 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.